134 related articles for article (PubMed ID: 27012075)
1. [THE PROGNOSTIC IMPACT OF CHROMOSOMAL ABERRATIONS IN TUMOR TISSUE BIOPSIES FROM PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA].
Fahoum I; Ziv M; Bar-El H; Attias D; Tadmor T
Harefuah; 2016 Jan; 155(1):45-9, 66. PubMed ID: 27012075
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics and Prognostic Significance of Cytogenetic Abnormalities in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement].
Liu W; Lyu R; Huang WY; Li CW; Liu H; Li J; Zou DH; Qiu LG; Yi SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):761-765. PubMed ID: 28641631
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of polyploid diffuse large B-cell lymphoma.
Shimono J; Miyoshi H; Kiyasu J; Kamimura T; Eto T; Miyagishima T; Nagafuji K; Seto M; Teshima T; Ohshima K
PLoS One; 2018; 13(4):e0194525. PubMed ID: 29641580
[TBL] [Abstract][Full Text] [Related]
5. [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma].
Wang XQ;
Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):656-60. PubMed ID: 17343195
[TBL] [Abstract][Full Text] [Related]
6. Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma.
Nanjangud G; Rao PH; Hegde A; Teruya-Feldstein J; Donnelly G; Qin J; Jhanwar SC; Zelenetz AD; Chaganti RS
Blood; 2002 Apr; 99(7):2554-61. PubMed ID: 11895793
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.
Mizuno Y; Tsukamoto T; Kawata E; Uoshima N; Uchiyama H; Yokota I; Maegawa S; Takimoto T; Tanba K; Matsumura-Kimoto Y; Kuwahara-Ota S; Fujibayashi Y; Yamamoto-Sugitani M; Chinen Y; Shimura Y; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Cancer Med; 2018 Mar; 7(3):655-664. PubMed ID: 29473332
[TBL] [Abstract][Full Text] [Related]
8. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
9. Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome.
Fiskvik I; Aamot HV; Delabie J; Smeland EB; Stokke T; Heim S; Holte H
Eur J Haematol; 2013 Oct; 91(4):332-8. PubMed ID: 23859481
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis in patients with diffuse large B cell lymphomas with bone marrow involvement possessing chromosomal abnormalities, despite aggressive treatment.
Min GJ; Jeon YW; Park SS; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Ann Hematol; 2020 Mar; 99(3):557-570. PubMed ID: 31989249
[TBL] [Abstract][Full Text] [Related]
11.
Tourneret A; Alame M; Rigau V; Bauchet L; Fabbro M; De Oliveira L; Cacheux V; Costes V; Lacheretz-Szablewski V
J Clin Pathol; 2021 Oct; 74(10):650-656. PubMed ID: 32912960
[TBL] [Abstract][Full Text] [Related]
12. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Klapper W; Stoecklein H; Zeynalova S; Ott G; Kosari F; Rosenwald A; Loeffler M; Trümper L; Pfreundschuh M; Siebert R;
Leukemia; 2008 Dec; 22(12):2226-9. PubMed ID: 18754028
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL).
Nedomova R; Papajik T; Prochazka V; Indrak K; Jarosova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Sep; 157(3):239-47. PubMed ID: 23132512
[TBL] [Abstract][Full Text] [Related]
14. Chromosome abnormalities in diffuse large B-cell lymphomas: analysis of 231 Chinese patients.
Zhao X; Fan R; Lin G; Wang X
Hematol Oncol; 2013 Sep; 31(3):127-35. PubMed ID: 23135954
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement.
Kim S; Kim H; Kang H; Kim J; Eom H; Kim T; Yoon SS; Suh C; Lee D;
J Hematol Oncol; 2013 Oct; 6():76. PubMed ID: 24220305
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma.
Nitsu N; Okamoto M; Miura I; Hirano M
Cancer Sci; 2009 Feb; 100(2):233-7. PubMed ID: 19038003
[TBL] [Abstract][Full Text] [Related]
17. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
Poirel HA; Cairo MS; Heerema NA; Swansbury J; Aupérin A; Launay E; Sanger WG; Talley P; Perkins SL; Raphaël M; McCarthy K; Sposto R; Gerrard M; Bernheim A; Patte C;
Leukemia; 2009 Feb; 23(2):323-31. PubMed ID: 19020548
[TBL] [Abstract][Full Text] [Related]
18. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
19. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.
Bea S; Zettl A; Wright G; Salaverria I; Jehn P; Moreno V; Burek C; Ott G; Puig X; Yang L; Lopez-Guillermo A; Chan WC; Greiner TC; Weisenburger DD; Armitage JO; Gascoyne RD; Connors JM; Grogan TM; Braziel R; Fisher RI; Smeland EB; Kvaloy S; Holte H; Delabie J; Simon R; Powell J; Wilson WH; Jaffe ES; Montserrat E; Muller-Hermelink HK; Staudt LM; Campo E; Rosenwald A;
Blood; 2005 Nov; 106(9):3183-90. PubMed ID: 16046532
[TBL] [Abstract][Full Text] [Related]
20. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
